Ariel talks about her journey of finally receiving a diagnosis of acute hepatic porphyria (AHP), a rare disease characterized by potentially life-threatening pain attacks. She is now able to manage her disease. She also discusses her experience being treated with Alnylam Pharmaceutical‘s GIVLAARI™ (givosiran) a drug approved by the FDA in November 2019 for the treatment of AHP.
Ariel is a patient diagnosed with AHP while raising two young children. After experiencing her first excruciating pain attack in 2010, Ariel’s symptoms stumped doctors for months until she finally received an accurate diagnosis and is now managing her disease.